论文部分内容阅读
目的检测35例ALL患儿诱导缓解治疗过程中血浆左旋门冬酰胺酶(L-Asp)活性以及抗L-Asp抗体水平变化,并分析它们之间的相关性。方法通过光度滴定法检测血浆L-Asp活性水平变化;通过ELISA方法检测血浆中抗L-Asp抗体永平变化。结果35例ALL患儿在诱导缓解治疗过程中,L-Asp活性始终保持在较高水平,中位活性为539U/L,无1例酶活性水平在100U/L以下;在L-Asp使用期间及停用后7天时,血浆中抗L-Asp抗体水平无明显变化,只是在停用第十天时抗体水平才有所升高,但与对L-Asp产生过敏患儿的抗体水平相比还有约4倍差距。结论ALL患儿诱导缓解治疗过程中使用L-Asp时血浆中抗L-Asp抗体的产生对L-Asp的作用无显著影响。
Objective To detect the changes of plasma L-Asp and anti-L-Asp antibody levels in 35 children with ALL during induction remission and analyze the correlation between them. Methods The level of plasma L-Asp activity was measured by photometric titration. The level of anti-L-Asp antibody in plasma was detected by ELISA. Results The 35 cases of ALL children with induced remission therapy, L-Asp activity remained at a high level, the median activity of 539U / L, no one enzyme activity level below 100U / L; L-Asp use period And 7 days after discontinuation of plasma anti-L-Asp antibody levels did not change significantly, but in the disabled on the tenth day antibody levels increased, but compared with the antibody levels in children with L-Asp allergy About 4 times the gap. Conclusions The anti-L-Asp antibody production in plasma with L-Asp induced by induction of remission in children with ALL has no significant effect on L-Asp.